Name: Tempest Therapeutics, Inc. (TPST) Financial Statements
Creator: FinSpry

Tempest Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Tempest Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.39	0.00	0.00	0.00	0.00
Gross Profit	-0.39	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	28.48	17.50	22.53	17.17	14.39
Selling, General & Administrative	13.55	11.66	12.11	9.82	4.91
Operating Expenses	42.03	29.16	34.64	26.99	19.30
Operating Income	-42.03	-29.16	-34.64	-26.99	-19.30
Other Income/Expense
Interest Income	1.50	1.12	0.60	0.01	0.09
Interest Expense	-1.32	1.45	1.62	1.28	0.00
Other Income/Expense	0.18	-1.12	-0.05	0.03	0.00
Income
Income Before Tax	-41.84	-28.04	-35.71	-28.30	-19.21
Income Tax Expense	0.00	-2.49	-2.73	-3.89	0.00
Net Income	-41.84	-29.49	-35.71	-28.30	-19.21
Net Income - Continuous Operations	-41.84	-29.49	-35.71	-28.30	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-41.64	-31.60	-33.45	-26.65	-18.96
EBIT	-42.03	-31.98	-34.09	-27.02	-19.30
Depreciation & Amortization	0.39	0.38	0.64	0.37	0.34
Earnings Per Share
Basic EPS	-19.00	-2.00	-3.00	-7.00	-533.00
Diluted EPS	-19.00	-2.00	-3.00	-7.00	-533.00
Basic Shares Outstanding	2.15	15.42	11.55	3.79	0.04
Diluted Shares Outstanding	2.15	15.42	11.55	3.79	0.04